electroCore Announces the Launch of Truvaga Plus® for General Wellness
April 08 2024 - 7:30AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, today announced the launch of its
direct-to-consumer mobile app-enabled product for general wellness,
Truvaga Plus, which will be available on www.truvaga.com beginning
April 8, 2024.
Our first general wellness product, Truvaga 350,
exceeded our expectations and Truvaga Plus will be an exciting
addition to the Truvaga brand. Truvaga Plus is engineered to
seamlessly integrate into daily routines and is a holistic and
convenient solution to manage stress and enhance overall
wellbeing.
Key features of Truvaga Plus include:
- Mobile App
Connectivity: Empowering users to control sessions, plan
schedules, and track progress conveniently through our integrated
mobile application.
- Unlimited
Sessions: Providing users with the flexibility for
prolonged usage and extended benefits, ensuring continuous support
for achieving optimal wellness.
- Rechargeable:
Enhancing sustainability and user convenience, Truvaga Plus
features a rechargeable design for uninterrupted usage.
- Compact Design:
Sleeker, smaller, and more portable, the new design of Truvaga Plus
ensures enhanced user comfort and convenience.
“I am thrilled to announce the launch of our
next generation, app-enabled general wellness product, Truvaga
Plus,” stated Dan Goldberger, CEO of electroCore. “Truvaga Plus
leverages the innovative non-invasive vagus nerve stimulation
technology of its predecessor, Truvaga 350, while offering enhanced
features and benefits to provide a drug-free solution for achieving
a healthier, more balanced lifestyle.”
Truvaga Plus is available for purchase
exclusively through electroCore’s eCommerce platform,
www.truvaga.com and comes with a 30-day risk-free money-back
guarantee. Complimentary, best in class 1:1 virtual training is
offered to every customer by the company’s customer experience
team.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine
and wellness company dedicated to improving health and promoting
general wellness through its non-invasive vagus nerve stimulation
(“nVNS”) technology platform. The company’s is focused on the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
About Truvaga Plus
Truvaga Plus is a revolutionary handheld vagus nerve stimulator
that utilizes the company’s proven technology to quickly and gently
activate the vagus nerve. It’s designed to work with the body to
balance the nervous system to feel calmer, think clearer, and sleep
better. Truvaga Plus is intended for general health and wellness
purposes only and is not intended to diagnose, cure, mitigate,
treat, or prevent any disease.
For more information, please visit www.truvaga.com.
Forward-Looking Statements
This press release and other written and oral statements made by
representatives of electroCore may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but
are not limited to, statements about electroCore's business
prospects, new and existing wellness product offerings, new
eCommerce site, and clinical and product development plans;
its pipeline or potential markets for its technologies; the timing,
outcome and impact of regulatory, clinical and commercial
developments including focus group study results; the Company’s
business prospects in the United States (including its e-commerce
initiatives) and other new markets and other statements that are
not historical in nature, particularly those that utilize
terminology such as "anticipates," "will," "expects," "believes,"
"intends," other words of similar meaning, derivations of such
words and the use of future dates. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to raise
the additional funding needed to continue to pursue electroCore’s
business and product development plans, the inherent uncertainties
associated with developing new products or technologies, the
ability to commercialize gammaCore™, the ability to successfully
launch and commercialize Truvaga Plus, the potential impact and
effects of COVID-19 on the business of electroCore, electroCore’s
results of operations and financial performance, and any measures
electroCore has and may take in response to COVID-19 and any
expectations electroCore may have with respect thereto, competition
in the industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Apr 2024 to May 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From May 2023 to May 2024